Podcast Interview with David Katz, PhD: Rett Syndrome and Ketamine

So many things about Rett are beyond our control. Accelerating a cure isn’t one of them. Sign up for the Registry now to help drive the development of genetic medicines. #ParentPowered

We are the organization working to cure Rett Syndrome.

You have the power to unlock a world of information, which will entice more Biopharma companies to take on Rett.

Check your RettList today to help us bring #PharmaToTable.

So many things about Rett are beyond our control. Accelerating a cure isn’t one of them. Sign up for the Registry now to help drive the development of genetic medicines. #ParentPowered

We are the organization working to cure Rett Syndrome.

You have the power to unlock a world of information, which will entice more Biopharma companies to take on Rett.

Check your RettList today to help us bring #PharmaToTable.

Donate

Join Us

Monica Coenraads, Executive Director of the Rett Syndrome Research Trust, interviews David Katz, PhD about his Journal of Neuroscience paper published 10/3/2012 and entitled "Brain Activity Mapping in Mecp2 Mutant Mice Reveals Functional Deficits in Forebrain Circuits, Including Key Nodes in the Default Mode Network, that are Reversed with Ketamine Treatment."

David Katz Interview

$40M

Take Action